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Abstract 
There is a need for researchers to have easy reference to the wide spectrum of different types of 
quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on 
QoL in AD do not cover the full spectrum of QoL measures used in studies on AD. This paper, 
on behalf of the European Academy of Dermatology and Venereology (EADV) Task Force on 
QoL contains information on instruments available for health-related QoL and family QoL 
assessment in AD including information on validation, experience of QoL assessment in AD for 
different purposes, peculiarities of QoL assessment in different age groups, expert analysis of 
available instruments including data on limitations of their use and recommendations of the Task 
Force.   
 
 
 
 
 
 
Introduction 
There is a need for researchers to have easy reference to the wide spectrum of different types of 
quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on 
QoL in AD do not cover the full spectrum of QoL measures used in studies on AD.1  A recent 
review on QoL instruments in adult AD2 did not identify a specific QoL instrument to be 
recommended for use in adult AD patients.  This paper, on behalf of the European Academy of 
Dermatology and Venereology (EADV) Task Force (TF) on QoL contains information on 
instruments available for health-related (HR) QoL and family QoL assessment in AD including 
information on validation, experience of QoL assessment in AD for different purposes, 
peculiarities of QoL assessment in different age groups, expert analysis of available instruments 
including data on limitations of their use and recommendations of the Task Force.  Although we 
do not attempt to define the “best” QoL instrument, the information provided should help 
dermatologists and researchers to choose appropriate QoL instruments and avoid common 
mistakes. 
Methods 
Members of the European Task Force on Atopic Dermatitis were invited to participate and Prof. 
Oranje agreed to join the working group. The literature search was performed using the PubMed 
database, which was searched from 1990 to November 2015 using the key word combinations: 
“Atopic dermatitis, quality of life” and “Atopic eczema, quality of life”.  All publications written 
in English or that had English abstracts were considered.  Duplicated and unrelated references 
and review articles were excluded. The remaining sources were analyzed and a list of QoL 
instruments that were used in AD was formed. Additional searches for “Name of measure” and 
“Atopic dermatitis/eczema” for each of the measures from this list was done. The results are 
presented in three sections: instruments for HRQoL and family QoL assessment in AD; 
peculiarities of QoL assessment in different age groups of patients with AD; reasons why QoL 
assessment may be useful in AD. 
Results 
HRQoL and family QoL instruments in AD 
A list of generic, dermatology-specific and AD-specific instruments with brief descriptions and 
information on validation are presented in Tables 1-3. In several publications42,43 the names of 
the QoL instruments used are not given.  In some other studies unvalidated “study-specific” 
instruments were used, some brief and simple44-47 and others more complicated.48-52 A 
“modified” DLQI was used in one study to measure the impairment of “itch-related” QoL.53 
Some QoL instruments with non-English original versions are given alternative titles in different 
publications. For example, Fragebogen Alltagsleben  (FAL), ALLTAG and “Daily life” are 
alternative titles of the same German instrument.16    
QoL assessment in different age groups of patients with AD 
We did not find information concerning specific aspects of HRQoL that may be affected 
differently in different age groups of adults with AD. There are several AD-specific HRQoL 
instruments created especially for children.  Most studies on QoL in young AD patients used the 
Infants Dermatitis Quality of Life Index (IDQoL)31. However, other AD-specific proxy-
instruments, the Childhood Atopic Dermatitis Impact Scale (CADIS) encompassing mixed proxy 
and family QoL37 and the Childhood Impact of Atopic Dermatitis (CIAD)40 were also used. The 
most widely used instrument for self-assessment of HRQoL in children with AD is the 
dermatology-specific Children’s Dermatology Life Quality Index (CDLQI).18 Several generic 
instruments have also been used to assess QoL of AD children: these include  Fragebogen für 
KINDer und Jugendlichezur Erfassung der gesundheitsbezogenen Lebensqualität  (KINDL)6, 
Quality of Life Scale for Children (AUQEI)7, DISABKIDS Chronic Generic Measure (DCGM-
37)10, Pediatric Quality of Life Inventory (PedsQL)15, Vécu et Santé Perçue de l'Adolescent 
(VSP-A) 14, Children's Quality of Life Index (CLQI)17, FAL/ALLTAG16 and AD-specific  
DISABKIDS AD Module (ADM)36. Because the lives of children alter greatly between the ages 
of 4 and 16 years, in the consideration of HRQoL children are not a homogenous group. Jirakova 
et al.54 divided children into two age groups, 7-13 years and 14-18 years, and found significant 
differences in two CDLQI items: problems in playing and doing hobbies and problems during 
school or holidays.  
Several AD-specific family QoL instruments have been created to try to measure the secondary 
impact of having someone in the family with AD on the QoL of other family members.  These 
include the Dermatitis Family Impact (DFI)34, Quality of life in Primary Caregivers of Children with 
AD (QPCAD)35, Parents' Index Quality of Life-AD (PIQoL-AD)38, The Quality of Life in Parents 
of Children with AD39 and CADIS (mixed proxy and family QoL instrument).37 The 
dermatology-specific Family Dermatology Life Quality Index (FDLQI) was created to measure 
the impact in family members of patients with all skin diseases and from all age groups.19 The 
FDLQI may be as effectively used by parents of children with AD as it can be used by family 
members of adult dermatology patients.55  
 
Use of Qol Measures in unvalidated or inappropriate age groups 
An important issue is the quite frequently reported use of HRQoL instruments out of their 
validated age limits. For example Skindex-29, an instrument for adults, was used in children 
from 13 years old56 and the DLQI, designed for use in those over 16 years old, was used in 
children from 8 years old.57 The CDLQI, originally validated for use in children from 4 to 16 
years old, was used in children aged 3 years58, 2 years59-62 and even 1 year of age.63,64 The 
IDQoL has been used in children under 654 and 7 years of age65, though it is only meant to be 
used in infants. Using this measure in older children was explained as being necessary because 
of the education system in the Czech Republic.54 The IDQOL is recommended to be used by 
children aged from newborn to 3 years of age and CDLQI by children from 4 to 16 years of age.  
The lower age cutoff was chosen because of the way in which a four year old behaves and the 
relevance of the questions to this age group.  Although reasons were given54 why in a study in 
the Czech Republic different age limits were applied for the use of the IDQoL and CDLQI, the 
original validated age recommendations remain those recommended by the authors. The scores 
of 33 teenagers with AD were presented as part of the data used for validation of the 
dermatology-specific Skindex-teen questionnaire.66 The generic HRQoL instrument for 
adolescents, VSP-A, was used in French children during the validation of the DISABKIDS 
instrument.10 The dermatology-specific CDLQI questionnaire67 has been used to study the 
specific problems experienced by adolescents. 
Reasons for assessment of QoL in AD  
Clinical trials 
Several different QoL instruments have been used in clinical trials of AD as outcome measures 
(Table 4). The DLQI and CDLQI have been the most frequently used, and the IDQoL and DFI 
are the most widely used AD-specific and infant and family QoL instruments. In some clinical 
trials “study-specific” non-validated instruments were used.45,49,47,119   Reports of other trials do 
not contain information on which HRQoL instruments were used.42,120 
Impairment of HRQoL and family QoL  
Several questionnaires were used simultaneously in studies of how QoL is impacted in AD 
patients and their families (Table 4).  
Creation and validation of instruments  
Several publications describe the creation and validation of QoL instruments, and their culturally 
validated local versions, in AD patients and in parents/caregivers (Table 4). The DLQI, DFI and 
PIQoL-AD have also been used in the validation process of non-QoL instruments.121-123  
Correlation of QoL and AD severity 
Many authors have presented data on the correlation of QoL and AD severity as a secondary 
outcome, but in addition there are several studies primarily aiming to study this correlation. 
Correlations have been reported between the generic measure Short Form Health Survey (SF-
36), dermatology-specific measures DLQI, CDLQI, Skindex-29, AD-specific measures IDQoL, 
the family QoL measure DFI, the German questionnaire “Quality of life in parents of children 
with atopic dermatitis”, and PIQoL-AD, along with scoring of AD (SCORAD), patient oriented 
(PO)-SCORAD, Eczema Area and Severity Index (EASI) and other AD severity scales.123-131 
There have been significant positive correlations between DLQI, IDQOL, DFI with SCORAD125-
126
, and some studies not finding such correlation.128,132 DLQI, DFI, IDQoL and CDLQI were 
well correlated with PO-SCORAD, suggesting the importance of the patient’s perspective.129-130 
Self-assessed HRQoL of children with AD correlated better with disease severity than family 
QoL results133. HRQoL measured by the DLQI, Skindex-29 and PIQoL-AD did not correlate 
with the severity of AD measured by the EASI.123-124  
Educational programs 
The QoL instruments that have been used to assess the efficacy of different educational 
programs are given in Table 4. The impact of support groups on HRQoL has been measured 
using the CDLQI, improving personal relationships and leisure time.103 DFI scores suggested 
that involvement with support groups103 or undertaking a two day parental education 
programme134 is not enough to improve family QoL.   However the importance of intensive 
educational programmes in children (5-16 years old) was confirmed by an improvement of the 
IDQOL, CDLQI and DFI scores.135  Web-based education programs had a beneficial effect on 
the HRQoL of AD children, as measured by the IDQoL.136 Parental counseling sessions about 
medical, nutritional and psychological issues improved treatment habits, costs and coping 
strategies in a study using the FAL/ALLTAG questionnaire.107  Another German questionnaire 
“QoL in parents of children with atopic dermatitis” was used to analyze the impact of longer 
educational programmes for parents of AD children and teenagers. There were better results in 
children less than 7 years old.137 The same measure was used to show that child-parent 
interventions could change the psychological parameters that could influence adherence and the 
success of therapy, by improving their coping strategies for control of scratching.105 Six weekly 
meetings as part of a multidisciplinary approach involving a pediatric allergist, dermatologist and 
psychologist had a significant improvement on IDQOL and DFI scores, also decreasing the 
levels of parents’ anxiety.104  DLQI and CDLQI scores have revealed the impact of daily text 
messages for six weeks as medication reminders and education for teens and adults.138 The on-
line self-management programme “Living with eczema” improves DLQI scores.139 DLQI and 
SCORAD scores were significantly improved by referral of atopic adults to secondary care, 
probably due to decreasing worries and concerns regarding their disease.140 
Impact of AD and other diseases 
Generic and dermatology-specific HRQoL instruments that have been used to compare the 
impact of AD and other diseases are given in Table 4. These studies confirmed that AD has a 
high impact on social functioning and psychological well-being, similar to other chronic 
dermatological conditions (psoriasis, Darier’s disease and Hailey-Hailey disease), hypertension, 
depression and type II diabetes.141 The use of the DLQI, Skindex-29 and the EQ-5D in large 
population studies showed lower QoL in people with self-reported skin diseases (including AD) 
than in the general population.108 Chronic diseases such as AD had a higher impact on QoL, as 
measured by the CDLQI and AUQEI, than molluscum contagiosum.117 In children, AD and 
psoriasis result in the highest CDLQI scores, followed by urticaria and acne.17 Vitiligo may 
cause greater impairment of HRQoL, assessed by the CDLQI, than AD.109 Generalized AD 
resulted in greater impairment of QoL than severe systemic diseases such as cystic fibrosis, 
asthma, epilepsy or diabetes.17 Skindex-29 scored more highly in AD than in “intrinsic AD”.56 
Use of the KINDL-R showed that acute AD and hay fever could have a higher impact on QoL 
than asthma.113 Young, single, poor patients with a long-duration of AD, psoriasis, vitiligo and 
acne report a lower QoL.142 Use of the generic measure, SF-12, has shown that psoriasis patients 
may experience a greater impact on their QoL and higher perceived stress than AD patients.112 
Using the DLQI and Skindex-16 it was shown that psoriasis has a higher effect on desire to be 
with people, showing affection and causing more problems with the treatment, whereas in AD 
itching causes higher negative impact on QoL. Psoriatic patients with only mild disease may 
experience a large negative effect on their QoL, a scenario not typical for AD patients.110 A 
study using the Adjustment to Chronic Skin Diseases Questionnaire (ACSD) suggested that the 
impact of psoriasis is greater than that of AD.118 Another study showed that only arthropathic 
psoriasis had a higher impact on HRQoL than AD, as measured by the SF-36 and the DLQI.143 
DLQI measurement showed that in both psoriasis and AD, hospitalization could have a positive 
effect on QoL.144 The willingness to pay in both AD and psoriasis correlates with DLQI 
scores.145 DLQI scores are better correlated with measures of depression, anxiety and personal 
interactions in AD than in vitiligo or healthy controls.146  
Other reasons to assess QoL in AD 
Other studies where QoL of AD patients and/or their families was studied are given in Table 5.  
Discussion 
The use of a wide range of QoL instruments has confirmed the impairment of QoL experienced 
by AD patients and their family members. Despite there being a range of reported correlations 
between HRQoL instruments and AD severity measures128,129, it is clear that HRQoL is generally 
more impaired in patients who have a more severe clinical course of AD.  
Generic instruments should be used to compare QoL impairment in AD with non-dermatologic 
conditions: dermatology-specific instruments may be used to compare QoL across different skin 
diseases. However, Twiss and McKenna176 used two disease-specific instruments that were 
created on the same principles (PSORIQoL and QoLIAD) to compare QoL impairment in AD 
and psoriasis. Dermatology-specific and disease-specific questionnaires may have a greater 
capacity for differentiation and be more sensitive to change than generic measures. Using a 
questionnaire which is not specifically tailored to the disease could mean that some issues 
associated with the disease are not recorded.177  When the  generic SF-36 was used in AD, there 
were only small score differences between patients with mild and moderate eczema and between 
mild eczema and healthy controls, and no significant correlation with AD severity, in contrast 
with reported correlations using the dermatology-specific DLQI and CDLQI.178  
There are many types of validated HRQoL instruments. Questionnaires should be tested for scale 
structure, reliability, validity and responsiveness. Additional validation methods are used to 
assess the quality of instruments. However some researchers have used “study-specific” 
instruments without any validation. Such practice negates the scientific value of the published 
results and may discredit HRQoL assessment. It is impossible to rely on the results of studies 
when authors do not mention the name of the QoL instrument used: authors should always give 
the names of any QoL instruments used in reported studies.  Where a single instrument has more 
than one descriptive title, the original title should be given, along with the original reference to 
its publication, in order to avoid confusion. Editors should ensure that published QoL data at 
least meets these minimum requirements. The use of modified versions of validated instruments 
is often described. However, such adapted questionnaires should be fully revalidated.  
As the QoL impacts experienced by people aged 16-17 may differ from those experienced 
by children or adults, QoL measures designed for use in this age range may have advantages over 
both child- and adult-specific measures.179 Though AD is relatively uncommon in the elderly, the 
numbers of elderly patients with AD are gradually increasing in industrialized countries, 
associated with an aging society.180  There may be specific ways in which elderly people are 
affected by AD that result in specific needs: prospective research is required to address this. 
It is possible to capture, with parental assistance, self assessment of QoL in children as young as 
four years old, with the help of illustrated questionnaires. In younger children outsider or proxy 
ratings can be used, but this brings with it the potential problem of adult-child concordance.181,182  
Because of possible discrepancy between self and proxy reports we recommend that proxy-rating 
questionnaires should only be used as a single measure in the youngest age group and in those 
patients who are unable to self-assess.  Spouses can report differing views, not associated with 
gender.183 Therefore it would seem better to involve both parents in completing proxy rated 
questionnaires, though this may be impractical. Cartoon versions of the questionnaires are 
preferable, especially for the youngest patients. 
Questionnaires should be selected that are appropriate for the ages of the subjects studied. If 
instruments have to be used out of their validated age limits, they should be revalidated.  
Some reports have combined scores of the DLQI and CDLQI: such combination is 
inappropriate184 as these instruments have different questions specific to the age groups for 
which the questionnaires are designed. The validated score banding descriptors, for example, are 
different. 
The selection of an appropriate HRQoL instrument in clinical research or practice depends on 
the research question and the target population in which the HRQoL instrument is 
administered.185  We recommend the use of validated AD-specific instruments in addition to 
generic and dermatology-specific questionnaires. The use of novel instruments with limited 
validation and lack of validated translations may meet the needs of a local study, but such use 
will inevitably limit comparability and interpretation of the results in a wider context.  Because 
of the significant family impact of AD we recommend that family QoL should be further studied, 
especially concerning young children. This may help to improve clinical consultations and 
choice of appropriate treatment strategy.  
This publication has focused on the large numbers of published research studies using QoL 
measures in AD.  However there is virtually no information about the routine use of QoL 
measures in the routine management of such patients, a question that is arguably of greater 
practical importance to clinicians.  If physicians choose to use a QoL measure in clinical 
practice, then issues such as simplicity of use and ability to interpret scores become of great 
importance. 
Limitations 
Because of space limitations and the high number of articles on QoL in AD, the number of 
references identified and reported per instrument in this paper may not reflect the actual 
frequency of the use of that instrument.  
Conclusion 
The summarized recommendations of the Task Force are presented in Table 6 and Figures 1 and 
2. This paper should help dermatologists and researchers to choose appropriate QoL instruments 
for their needs and avoid common mistakes. 
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